Introduction {#Sec1}
============

Background {#Sec2}
----------

Hyperglycemia in type 2 diabetes mellitus (T2DM) is caused by defects in the insulin secretory response from pancreatic β-cells and in insulin action on skeletal muscles, adipose tissues, and the liver. Impaired insulin action, or insulin resistance, is closely related to abdominal fat deposition and also accelerates cardiovascular complications. Patients with T2DM are being treated with either oral antidiabetic agents (OADs) or injectable agents, or both. Patients are often reluctant to start an injectable medication, since it may be painful and restrict their daily life activities. Japanese patients with T2DM are usually treated, after lifestyle modification, with either biguanides, sulfonylureas (SU), or DPP-4 inhibitors (DPP-4i) \[[@CR1]\]. Biguanide and DPP-4i combination is the dual therapy most commonly used in Japan \[[@CR2]\]. However, when glycemic control is not adequate despite these drugs, there is no consensus on the next step drug. Clinicians are advised to evaluate individual patients to ascertain the optimal therapy for each \[[@CR3]\].

Sulfonylurea drugs, used for more than 50 years, stimulate insulin secretion and suppress glucose levels. The efficacy of SUs for controlling blood glucose is well recognized, and these agents are often used as the second- or third-line OAD, or even as the first drug \[[@CR1], [@CR2]\]. Beneficial effects of combination therapy with a DPP-4 inhibitor have also been reported \[[@CR4], [@CR5]\]. Furthermore, SUs are economical to use. However, SUs may cause hypoglycemia, especially when combined with a DPP-4i \[[@CR6]\]. SUs may also cause weight gain, although there are reportedly inconsistent results when combined with metformin and/or a DPP-4i in Japanese patients \[[@CR4]\]. It is noteworthy that the latest generation SU, glimepiride, may exert extra-pancreatic effects enhancing insulin sensitivity \[[@CR7]--[@CR10]\].

Recently, sodium glucose cotransporter-2 inhibitors (SGLT2i) have emerged as promising treatments for T2DM. This class of drugs inhibits glucose reabsorption from urine, a mechanism independent of insulin action, which makes them appropriate for use with pre-existing agents. In addition, as a result of glucose loss from urine, body weight is often reduced when taking these drugs. They also exhibit pleiotropic effects on diabetic complications including heart failure, renal impairment, and hepatic dysfunction \[[@CR11]--[@CR13]\]. Tofogliflozin is an SGLT2i with 2900-fold greater selectivity for SGLT2 than SGLT1 and has the highest selectivity of all clinically developed inhibitors \[[@CR14]\]. Randomized controlled studies in Japanese T2DM patients with inadequate glycemic control on diet/exercise therapy \[[@CR15]\] or on other OADs \[[@CR16]\] demonstrated that tofogliflozin significantly improved glycemic control and decreased body weight.

Several investigations have compared the efficacy and safety of an SU and an SGLT2i as second-line drugs after metformin: canagliflozin vs. glimepiride \[[@CR17]\], empagliflozin vs. glimepiride \[[@CR18]\], and dapagliflozin vs. glipizide \[[@CR19]\]. SUs initially produced a greater drop in HbA1c but were essentially equivalent in efficacy to an SGLT2i after 52 weeks. Hypoglycemia was more frequent in the SU groups in all three trials, while genital infections were observed more frequently in the SGLT2i groups. Systematic reviews or meta-analyses of previous trials have indicated that glycemic control by triple combination therapy yielded similar results \[[@CR20]--[@CR22]\]. Therefore, other merits besides glycemic control as well as disadvantages should be considered: for example, less hypoglycemia, less weight gain, and beneficial effects on cardiovascular risks. One of the prominent features of SGLT2i is the effects on cardiovascular complications \[[@CR11]--[@CR13]\]. Although the precise mechanisms by which SGLT2i exert beneficial effects on the cardiovascular system are unknown, diminished insulin resistance appears to play a role, which is closely related to reduced body weight and loss of fat. Although several reports have indicated body fat loss by SGLT2i \[[@CR23]--[@CR26]\] as possibly leading to improvement of insulin sensitivity, glimepiride has also been shown to have some effects on insulin sensitivity as well as possible extra-pancreatic effects \[[@CR7]--[@CR10]\].

Objectives and Trial Design {#Sec3}
---------------------------

In this trial, therefore, we are attempting to compare the change in body fat percentage and insulin resistance parameters between patients, with either tofogliflozin or glimepiride added as the third-line agent, who have not achieved adequate glycemic control when treated with metformin and a DPP-4i. For this purpose, we have designed this multicenter, prospective, randomized, open-label, parallel-group trial.

Methods {#Sec4}
=======

Study Design {#Sec5}
------------

Sodium glucose cotransporter-2 inhibitor, tofogliflozin versus glimepiride comparative trial in patients with type 2 diabetes on body composition (STOP-OB) is an ongoing, multicenter, prospective, randomized, open-label, parallel-group trial. This trial was designed to compare tofogliflozin (20 mg/day) and glimepiride (0.5 mg/day) as third-line oral agents on top of metformin and DPP-4is. Patients are randomized to either the tofogliflozin group or the glimepiride group (ratio 1:1) using the web-based minimization method for HbA1c level (\< 8.0%, ≥ 8.0%) and body mass index (BMI) (\< 25.0, ≥ 25.0 kg/m^2^), at the time of providing informed consent. Following 24 weeks of treatment, clinical and biochemical data, including body composition, will be evaluated. All personal information and data will be anonymized.

This study has been registered on the University Hospital Medical Information Network Clinical Trials Registry (UMIN-CTR), which is a non-profit organization in Japan, and meets the requirements of the International Committee of Medical Journal Editors (ICMJE) (UMIN000026161).

The study protocol was approved by the institutional review board at each participating institution in compliance with the Declaration of Helsinki and current legal regulations in Japan. The study will be conducted in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects published by the Ministry of Health, Labor and Welfare of Japan and the Helsinki Declaration of 1964, as revised in 2013. Written informed consent for participation is to be obtained from all participants after a full explanation of the study has been provided by investigators. Any changes in the protocol will be submitted to the institutional review boards.

Sample Selection {#Sec6}
----------------

Japanese T2DM subjects who periodically come to the outpatient clinics for diabetes at ten institutions in Japan (Supplementary Table 1) will be asked to participate in this study. The inclusion and exclusion criteria are as follows:

Inclusion criteria

T2DM patients treated with any of the DPP-4is and metformin (≥ 500 and ≤ 1500 mg/day) without dose changes for at least 4 weeks before the time of providing informed consent.HbA1c levels of at least 7.0% but less than 9.0% at the time of providing informed consent.Age ≥ 20 and \< 75 years (regardless of gender).Provision of written consent for participation in the study.

Exclusion criteria

Type 1 or secondary diabetes.Use of antidiabetic drugs other than DPP-4is and metformin (including insulins and GLP-1 receptor agonists) 12 weeks prior to provision of consent.Dose changes or start of medication of diuretics 12 weeks prior to provision of consent.BMI less than 18.5 (kg/m^2^) or at least 35.Contraindication or hypersensitivity to SGLT2is or SUs.Moderate or severe renal dysfunction (eGFR \< 60 mL/min/1.73 m^2^).Severe liver dysfunction.History of stroke or cerebral infarction.For women, pregnant, lactating, possibly pregnant, or planning to become pregnant.Moderate or severe heart failure (NYHA/New York Heart Association stage III or more severe).Urinary tract or genital infections.Cancer or history of cancer (study inclusion possible if recurrence is confirmed to be absent).Judged to be ineligible for any reason (such as steroid use or weight loss medication) by the clinical investigators.

Treatment {#Sec7}
---------

Participants treated with metformin and a DPP-4i are to be additionally given either tofogliflozin (20 mg/day) or glimepiride (0.5 mg/day) after breakfast every day for 24 weeks. Treatment with tofogliflozin is to be followed by the official recommendation for appropriate use of SGLT2is from the Japan Diabetes Society. Each participant's regimen other than the study drugs will remain unchanged, with no drugs being either added or discontinued after provision of informed consent.

Observation Items and Schedule {#Sec8}
------------------------------

The observation items and schedule are shown in Fig. [1](#Fig1){ref-type="fig"}. The study period is 24 weeks after the initial administration of the study drugs (registration period, January 2017--March 2018; full study duration, January 2017--December 2018). All randomized participants will be followed until the scheduled study completion, regardless of adherence to or discontinuation of study medication for any reason. The clinical outcomes, adherence, and adverse events will be ascertained, and clinical and biochemical data will be collected at 0, 12, and 24 weeks after randomization.Fig. 1Study design

Planned Outcomes {#Sec9}
----------------

The primary study outcome is the change in body fat percentage from baseline to 24 weeks. The secondary outcomes are changes in the following parameters from baseline to week 24:Body composition other than fat percentage (fat content, fat-free mass, muscle mass, total body water, total body water percentage, bone mass, basal metabolic rate (BMR), visceral fat rating, leg muscle score, and degree of obesity).Body weight, BMI, abdominal circumference, and blood pressure.Parameters related to glycemic control and β-cell function (HbA1c, plasma glucose, insulin, C-peptide, glucagon, HOMA-β, and HOMA-R).Parameters related to lipids and arteriosclerosis (serum total cholesterol, HDL-cholesterol, triglyceride, LDL-cholesterol, adiponectin, and leptin).Parameters related to liver function (AST, ALT, γGTP, ketone bodies, type IV collagen 7S, ferritin, and hyaluronic acid).Parameters related to diabetic nephropathy (serum creatinine, urinary albumin, and eGFR).Serum uric acid.Any adverse events, including hypoglycemia.Drug adherence rates.

Body fat percentages, fat content, fat-free mass, muscle mass, total body water, total body water percentage, bone mass, BMR, BMR level, visceral fat rating, leg muscle rating, and degree of obesity will be measured using the dual cycle several composition DC-430A body composition analyzer (Tanita, Tokyo, Japan), which is the latest model after the DC-320 \[[@CR27], [@CR28]\]. Plasma glucose, insulin, C-peptide, and glucagon will be measured by 75 g oral glucose tolerance test (OGTT) at the following four measurement time points: before glucose intake (pre) and 0.5 h, 1 h, and 2 h after glucose intake. The OGTT will be conducted with the subject in a fasted state at baseline and at week 24. In the OGTT at week 24, participants will take their allocated study drugs after the pre-measurement and before glucose intake.

Safety Evaluation {#Sec10}
-----------------

The details and incidence of adverse events will be periodically ascertained. If the investigators identify any adverse events, the severity grades, procedures, outcomes, and relationships to the study drugs will be assessed and recorded on the case report form. For compensation to those who suffer harm from the study participation, clinical trial insurance will be provided.

Sample Size {#Sec11}
-----------

A preceding study \[[@CR17]\] found that body fat percentage changed in response to 52-week treatments with empagliflozin and glimepiride by − 0.6% and 1.1%, respectively. We estimated changes in the body fat percentage after 24-week treatments with tofogliflozin and glimepiride to be − 0.6 ± 2.2% and 1.1 ± 2.2%, respectively. On the basis of these estimations and with a two-sided significance level of 5% and power of 80%, the number of patients required to detect a significant difference in the change in the body fat percentage between the two groups was 28 patients per group, requiring a total sample size of 56. Assuming a 10% dropout rate during the study, we set the target number of patients at 32 per group, i.e., a total of 64 patients.

Data Analysis {#Sec12}
-------------

The primary and secondary outcomes, except for adverse events, will be analyzed using mainly the full analysis set (FAS) and the secondary per protocol set (PPS). The FAS includes all participants enrolled and randomized except for those with serious violations of the study protocol such as failing to provide informed consent and enrollment outside of the study period. The PPS includes participants excluded, as a result of any violation of the inclusion/exclusion criteria, use of prohibited drugs concomitantly, and poor compliance with the study drugs (\< 75%, ≥ 120%), from the FAS population. On the other hand, we will perform an analysis of adverse events using a safety analysis set, which will include all enrolled participants and those treated with any of the study agents.

The primary endpoint, the change in body fat percentage, will be analyzed using analysis of covariance models including the treatment group as the fixed effect and the baseline HbA1c level and BMI as covariances. In addition, as the sensitivity analysis, we plan to apply the mixed effects model for repeated measures including treatment group and time, the interaction between treatment group and time, the baseline HbA1c level and BMI as fixed effects, and with an unstructured covariance within-subject variability. For continuous variables of the secondary endpoints, we will perform Student's *t* test for comparisons between groups, and the one-sample*t* test for within-group changes. In the analysis of adverse events, Fisher's exact test will be applied for comparisons between groups. All statistical analyses will be two-tailed at a significance level of 0.05, using SAS software version 9.4 (SAS Institute, Cary, NC, USA). The planned analysis will be described in detail in the statistical analysis plan that will be developed by the principal investigator and a biostatistician and fixed before locking of the database.

Strengths and Limitations {#Sec13}
-------------------------

The strength of this trial is a multicenter, prospective, randomized, controlled, parallel-group design. To the best of our knowledge, this is the first trial comparing the effects and safety of an SGLT2i and an SU added as the third-line oral agent to metformin/DPP-4i dual therapy. The limitations are the small number of participants and the open label trial design. In addition, although we consider the bio-impedance method to be satisfactory and convenient for measuring body fat mass but dual-energy X-ray absorptiometry, quantitative computer tomography, or magnetic resonance imaging might be an alternative.
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